Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
Shortly after posting our last blog on tacicepts, new data was published in the NEJM on the pivotal Phase 3 trial of atacicept. This publication by Lafayette et al. provides results from an IA of the ongoing ORIGIN-3 trial.[1] We Continue reading COMPARISON OF BAFF / APRIL INHIBITORS – 2
First, a reminder where the name ‘Berger’s disease’ or Morbus Berger comes from. It was Jean Berger, a French pathologist and doctor, who initially identified IgA deposits on the glomeruli of nephritic patients. This was not so long ago; his publication Continue reading COMPARISON OF BAFF / APRIL INHIBITORS
In today’s blog we will share our thoughts about a recent NEJM article, entitled “A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus”.[1] Publications on SLE literally come with a book of abbreviations and definitions nowadays and are not Continue reading TELITACICEPT IN SLE
As many in the field have said before, what we really need are antifungals with a truly novel MoA, not minor changes to well-established classes.[1] There is a shortage of new antifungals for invasive disease. Small improvements in PK will hardly Continue reading The Antifungal Landscape – 2
The early work on the organism and the toxoid vaccine reads like the ‘Who Is Who’ of microbiology: Klebs, Loeffler, Koch, Roux, Yersin, Behring, Kitasato, Schick, and T. Smith were all involved in bringing this deadly disease under control. In Continue reading About DIPHTHERIA